BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35800054)

  • 1. PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas.
    Liu Y; Xiang J; Peng G; Shen C
    Front Oncol; 2022; 12():620190. PubMed ID: 35800054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
    Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
    Front Oncol; 2020; 10():1409. PubMed ID: 32974146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer.
    Bi F; Chen Y; Yang Q
    Cancer Cell Int; 2020; 20():373. PubMed ID: 32774167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
    Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
    Xu S; Wang Z; Ye J; Mei S; Zhang J
    Front Oncol; 2021; 11():729103. PubMed ID: 34568059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis of the disulfidptosis-related gene
    Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
    Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 11. A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients.
    Xiang Z; Chen X; Lv Q; Peng X
    Front Genet; 2021; 12():697819. PubMed ID: 34408772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Mutation Burden-Related Histopathologic Features for Predicting Overall Survival in Gliomas Using Graph Deep Learning.
    Sun C; Luo T; Liu Z; Ge J; Shao L; Liu X; Li B; Zhang S; Qiu Q; Wei W; Wang S; Bian XW; Tian J
    Am J Pathol; 2023 Dec; 193(12):2111-2121. PubMed ID: 37741452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prognostic Microenvironment-Related Immune Signature
    Qiu H; Li Y; Cheng S; Li J; He C; Li J
    Front Oncol; 2020; 10():580263. PubMed ID: 33425732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
    Kang K; Xie F; Mao J; Bai Y; Wang X
    Front Oncol; 2020; 10():573141. PubMed ID: 33072607
    [No Abstract]   [Full Text] [Related]  

  • 18. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
    Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
    Front Immunol; 2020; 11():603341. PubMed ID: 33363544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis.
    Yan J; Wu X; Yu J; Zhu Y; Cang S
    Front Oncol; 2020; 10():570654. PubMed ID: 33240814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
    Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
    Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.